

Christian Simader

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3249779/publications.pdf>

Version: 2024-02-01

66
papers

9,195
citations

134610

34
h-index

162838

57
g-index

66
all docs

66
docs citations

66
times ranked

5511
citing authors

#	ARTICLE	IF	CITATIONS
1	Association of Changes in Macular Perfusion With Ranibizumab Treatment for Diabetic Macular Edema. <i>JAMA Ophthalmology</i> , 2018, 136, 315.	1.4	24
2	The Decreasing Prevalence of Nonrefractive Visual Impairment in Older Europeans. <i>Ophthalmology</i> , 2018, 125, 1149-1159.	2.5	20
3	Predictive imaging biomarkers relevant for functional and anatomical outcomes during ranibizumab therapy of diabetic macular oedema. <i>British Journal of Ophthalmology</i> , 2018, 102, 195-203.	2.1	68
4	The Distribution of Leakage on Fluorescein Angiography in Diabetic Macular Edema: A New Approach to Its Etiology. , 2017, 58, 3986.		25
5	Impact of B-Scan Averaging on Spectralis Optical Coherence Tomography Image Quality before and after Cataract Surgery. <i>Journal of Ophthalmology</i> , 2017, 2017, 1-8.	0.6	4
6	Multivendor Spectral-Domain Optical Coherence Tomography Dataset, Observer Annotation Performance Evaluation, and Standardized Evaluation Framework for Intraretinal Cystoid Fluid Segmentation. <i>Journal of Ophthalmology</i> , 2016, 2016, 1-8.	0.6	22
7	A novel benchmark model for intelligent annotation of spectral-domain optical coherence tomography scans using the example of cyst annotation. <i>Computer Methods and Programs in Biomedicine</i> , 2016, 130, 93-105.	2.6	9
8	Morphology and Visual Acuity in Aflibercept and Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration in the VIEW Trials. <i>Ophthalmology</i> , 2016, 123, 1521-1529.	2.5	124
9	Intravitreal Aflibercept for Diabetic Macular Edema. <i>Ophthalmology</i> , 2016, 123, 2376-2385.	2.5	329
10	Correlation of 3-Dimensionally Quantified Intraretinal and Subretinal Fluid With Visual Acuity in Neovascular Age-Related Macular Degeneration. <i>JAMA Ophthalmology</i> , 2016, 134, 182.	1.4	80
11	Choroidal thickness maps from spectral domain and swept source optical coherence tomography: algorithmic versus ground truth annotation. <i>British Journal of Ophthalmology</i> , 2016, 100, 1372-1376.	2.1	34
12	Choroidal Line Scan Measurements in Swept-Source Optical Coherence Tomography as Surrogates for Volumetric Thickness Assessment. <i>American Journal of Ophthalmology</i> , 2016, 162, 150-158.e1.	1.7	5
13	Predictive Value of Retinal Morphology for Visual Acuity Outcomes of Different Ranibizumab Treatment Regimens for Neovascular AMD. <i>Ophthalmology</i> , 2016, 123, 60-69.	2.5	97
14	Differentiation of Diabetic Macular Edema From Pseudophakic Cystoid Macular Edema by Spectral-Domain Optical Coherence Tomography. , 2015, 56, 6724.		61
15	Pigment Epithelial Detachment Followed by Retinal Cystoid Degeneration Leads to Vision Loss in Treatment of Neovascular Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2015, 122, 822-832.	2.5	170
16	Intravitreal Aflibercept for Diabetic Macular Edema. <i>Ophthalmology</i> , 2015, 122, 2044-2052.	2.5	451
17	Quantitative comparison of macular segmentation performance using identical retinal regions across multiple spectral-domain optical coherence tomography instruments. <i>British Journal of Ophthalmology</i> , 2015, 99, 794-800.	2.1	34
18	Efficacy and safety of intravitreal aflibercept injection in wet age-related macular degeneration: outcomes in the Japanese subgroup of the VIEW 2 study. <i>British Journal of Ophthalmology</i> , 2015, 99, 92-97.	2.1	45

#	ARTICLE	IF	CITATIONS
19	Influence of Orthostasis and Daytime on Retinal Thickness in Uveitis-Associated Cystoid Macular Edema. <i>Current Eye Research</i> , 2014, 39, 395-402.	0.7	5
20	A systematic correlation of morphology and function using spectral domain optical coherence tomography and microperimetry in patients with geographic atrophy. <i>British Journal of Ophthalmology</i> , 2014, 98, 1050-1055.	2.1	43
21	Intraretinal cysts are the most relevant prognostic biomarker in neovascular age-related macular degeneration independent of the therapeutic strategy. <i>British Journal of Ophthalmology</i> , 2014, 98, 1629-1635.	2.1	67
22	DIFFERENTIAL DIAGNOSIS OF MACULAR EDEMA OF DIFFERENT PATHOPHYSIOLOGIC ORIGINS BY SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY. <i>Retina</i> , 2014, 34, 2218-2232.	1.0	35
23	Intravitreal Aflibercept Injection for Macular Edema Resulting from Central Retinal Vein Occlusion. <i>Ophthalmology</i> , 2014, 121, 202-208.	2.5	243
24	Intravitreal Aflibercept for Macular Edema Secondary to Central Retinal Vein Occlusion: 18-Month Results of the Phase 3 GALILEO Study. <i>American Journal of Ophthalmology</i> , 2014, 158, 1032-1038.e2.	1.7	142
25	Three-Dimensional Automated Choroidal Volume Assessment on Standard Spectral-Domain Optical Coherence Tomography and Correlation With the Level of Diabetic Macular Edema. <i>American Journal of Ophthalmology</i> , 2014, 158, 1039-1048.e1.	1.7	70
26	Intravitreal Aflibercept for Diabetic Macular Edema. <i>Ophthalmology</i> , 2014, 121, 2247-2254.	2.5	668
27	Impact of Vitreomacular Adhesion on Ranibizumab Mono- and Combination Therapy for Neovascular Age-Related Macular Degeneration. <i>American Journal of Ophthalmology</i> , 2014, 158, 328-336.e1.	1.7	35
28	Intravitreal Aflibercept Injection for Neovascular Age-related Macular Degeneration. <i>Ophthalmology</i> , 2014, 121, 193-201.	2.5	693
29	Morphologic Parameters Relevant for Visual Outcome During Anti-Angiogenic Therapy of Neovascular Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2014, 121, 1237-1245.	2.5	146
30	A Longitudinal Comparison of Spectral-Domain Optical Coherence Tomography and Fundus Autofluorescence in Geographic Atrophy. <i>American Journal of Ophthalmology</i> , 2014, 158, 557-566.e1.	1.7	37
31	One Year Follow-up of Functional Recovery in Neovascular AMD During Monthly Anti-VEGF Treatment. <i>American Journal of Ophthalmology</i> , 2013, 156, 633-643.e2.	1.7	34
32	VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study. <i>British Journal of Ophthalmology</i> , 2013, 97, 278-284.	2.1	196
33	Influence of the Vitreomacular Interface on Outcomes of Ranibizumab Therapy in Neovascular Age-related Macular Degeneration. <i>Ophthalmology</i> , 2013, 120, 2620-2629.	2.5	74
34	Two-Year Safety and Efficacy of Ranibizumab 0.5 mg in Diabetic Macular Edema. <i>Ophthalmology</i> , 2013, 120, 2004-2012.	2.5	112
35	Systematic correlation of morphologic alterations and retinal function in eyes with uveitis-associated cystoid macular oedema during development, resolution and relapse. <i>British Journal of Ophthalmology</i> , 2013, 97, 1289-1296.	2.1	17
36	THERAPEUTIC INTERVENTIONS FOR MACULAR DISEASES SHOW CHARACTERISTIC EFFECTS ON NEAR AND DISTANCE VISUAL FUNCTION. <i>Retina</i> , 2013, 33, 1915-1922.	1.0	10

#	ARTICLE	IF	CITATIONS
37	MORPHOLOGIC AND FUNCTIONAL EVALUATIONS DURING DEVELOPMENT, RESOLUTION, AND RELAPSE OF UVEITIS-ASSOCIATED CYSTOID MACULAR EDEMA. <i>Retina</i> , 2013, 33, 1673-1683.	1.0	36
38	INFLUENCE OF VITREOMACULAR ADHESION ON THE DEVELOPMENT OF EXUDATIVE AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2012, 32, 424-433.	1.0	22
39	Verteporfin plus Ranibizumab for Choroidal Neovascularization in Age-related Macular Degeneration. <i>Ophthalmology</i> , 2012, 119, 992-1000.	2.5	119
40	Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration. <i>Ophthalmology</i> , 2012, 119, 2537-2548.	2.5	1,947
41	Efficacy and Safety of Monthly versus Quarterly Ranibizumab Treatment in Neovascular Age-related Macular Degeneration: The EXCITE Study. <i>Ophthalmology</i> , 2011, 118, 831-839.	2.5	353
42	The RESTORE Study. <i>Ophthalmology</i> , 2011, 118, 615-625.	2.5	1,212
43	A Systematic Comparison of Spectral-Domain Optical Coherence Tomography and Fundus Autofluorescence in Patients with Geographic Atrophy. <i>Ophthalmology</i> , 2011, 118, 1844-1851.	2.5	107
44	Changes in macular sensitivity after reduced fluence photodynamic therapy combined with intravitreal triamcinolone. <i>Acta Ophthalmologica</i> , 2011, 89, 166-171.	0.6	7
45	Quantification of the Therapeutic Response of Intraretinal, Subretinal, and Subpigment Epithelial Compartments in Exudative AMD during Anti-VEGF Therapy. , 2011, 52, 1599.		77
46	Effects of Lutein Supplementation on Macular Pigment Optical Density and Visual Acuity in Patients with Age-Related Macular Degeneration. , 2011, 52, 8174.		131
47	Evaluation of optical coherence tomography findings in age-related macular degeneration: a reproducibility study of two independent reading centres. <i>British Journal of Ophthalmology</i> , 2011, 95, 381-385.	2.1	34
48	In Vivo Retinal Morphology after Grid Laser Treatment in Diabetic Macular Edema. <i>Ophthalmology</i> , 2010, 117, 538-544.	2.5	52
49	High-Resolution Optical Coherence Tomography after Surgery for Vitreomacular Traction. <i>Ophthalmology</i> , 2010, 117, 2010-2017.e2.	2.5	38
50	Time-course and characteristic morphology of retinal changes following combination of verteporfin therapy and intravitreal triamcinolone in neovascular age-related macular degeneration. <i>Acta Ophthalmologica</i> , 2010, 88, 212-217.	0.6	3
51	Role of NO in the Control of Choroidal Blood Flow during a Decrease in Ocular Perfusion Pressure. , 2009, 50, 372.		32
52	Evaluation of Ranibizumab-Induced Changes in High-Resolution Optical Coherence Tomographic Retinal Morphology and Their Impact on Visual Function. , 2009, 50, 2376.		61
53	A Systematic Correlation of Angiography and High-Resolution Optical Coherence Tomography in Diabetic Macular Edema. <i>Ophthalmology</i> , 2009, 116, 66-72.	2.5	70
54	Association of Retinal Sensitivity and Morphology during Antiangiogenic Treatment of Retinal Vein Occlusion over One Year. <i>Ophthalmology</i> , 2009, 116, 2415-2421.	2.5	47

#	ARTICLE	IF	CITATIONS
55	CHANGES IN RETINAL SENSITIVITY IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION AFTER SYSTEMIC BEVACIZUMAB (AVASTIN) THERAPY. <i>Retina</i> , 2008, 28, 682-688.	1.0	31
56	Regulation of Choroidal Blood Flow during Combined Changes in Intraocular Pressure and Arterial Blood Pressure. , 2007, 48, 3768.		156
57	Rapid improvement of radiation-induced neovascular glaucoma and exudative retinal detachment after a single intravitreal ranibizumab injection. <i>Clinical and Experimental Ophthalmology</i> , 2007, 35, 878-880.	1.3	30
58	Retinal Pigment Epithelium Tears Following Verteporfin Therapy Combined With Intravitreal Triamcinolone. <i>American Journal of Ophthalmology</i> , 2006, 141, 396-398.e1.	1.7	43
59	C-Peptide Does Not Affect Ocular Blood Flow in Patients With Type 1 Diabetes. <i>Diabetes Care</i> , 2006, 29, 2034-2038.	4.3	7
60	VERTEPORFIN THERAPY FOR CHOROIDAL HEMANGIOMA: A LONG-TERM FOLLOW-UP. <i>Retina</i> , 2005, 25, 697-703.	1.0	60
61	Short-Term Increase of Intraocular Pressure Does Not Alter the Response of Retinal and Optic Nerve Head Blood Flow to Flicker Stimulation. , 2005, 46, 1721.		54
62	Contrast sensitivity function in eyes with diffractive bifocal intraocular lenses. <i>Journal of Cataract and Refractive Surgery</i> , 2005, 31, 2076-2083.	0.7	32
63	Influence of spectacle-related changes in retinal image size on contrast sensitivity function after laser in situ keratomileusis. <i>Journal of Cataract and Refractive Surgery</i> , 2004, 30, 626-632.	0.7	8
64	Long-term results of implantation of phakic posterior chamber intraocular lenses. <i>Journal of Cataract and Refractive Surgery</i> , 2004, 30, 2269-2276.	0.7	130
65	Clare and halo phenomena after laser in situ keratomileusis. <i>Journal of Cataract and Refractive Surgery</i> , 2003, 29, 444-450.	0.7	58
66	Stable registration of pathological 3D-OCT scans using retinal vessels. , 0, , .		9